Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 1.00 |
| ▸ | SRC | P12931 | 11/20 | 1.00 |
| ▸ | TEK | Q02763 | 10/20 | 1.00 |
| ▸ | HCK | P08631 | 9/20 | 0.82 |
| ▸ | KDR | P35968 | 7/20 | 0.82 |
| ▸ | FLT3 | P36888 | 5/20 | 0.82 |
| ▸ | LYN | P07948 | 3/20 | 0.82 |
| ▸ | EGFR | P00533 | 2/20 | 0.82 |
| ▸ | FYN | P06241 | 2/20 | 0.82 |
| ▸ | CSK | P41240 | 2/20 | 0.82 |
| ▸ | BTK | Q06187 | 2/20 | 0.82 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.82 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.82 |
| ▸ | PAK4 | O96013 | 2/20 | 0.82 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.82 |
| ▸ | INSR | P06213 | 2/20 | 0.82 |
| ▸ | CSF1R | P07333 | 2/20 | 0.82 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.82 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.82 |
| ▸ | MARK3 | P27448 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6459046 | 1.00 | LCK (1.00) | LCKSRCTEKHCKKDR | |
| SCHEMBL6861908 | 1.00 | LCK (1.00) | LCKSRCTEKHCKKDR | |
| Hydrochloric Acid SCHEMBL6460649 | 0.99 | LCK (0.98) | LCKSRCTEKHCKKDR | |
| Hydrochloric Acid SCHEMBL6460645 | 0.99 | LCK (0.98) | LCKSRCTEKHCKKDR | |
| SCHEMBL6458486 | 0.99 | LCK (0.98) | LCKSRCTEKHCKKDR | |
| SCHEMBL6460765 | 0.99 | LCK (0.98) | LCKSRCTEKHCKKDR | |
| SCHEMBL6458490 | 0.99 | LCK (0.98) | LCKSRCTEKHCKKDR | |
| SCHEMBL23854913 | 0.92 | LCK (0.84) | LCKSRCTEKHCKKDR | |
| SCHEMBL23847522 | 0.92 | LCK (0.84) | LCKSRCTEKHCKKDR | |
| SCHEMBL23847515 | 0.92 | LCK (0.84) | LCKSRCTEKHCKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | claimed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | claimed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | claimed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | claimed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| WO-2004100868-A2 | METHOD OF TREATING TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| CN-1335849-A | Pyrrolopyrimidines as protein kinase inhibitors | BASF AG (DE) | 2002-02-13 | — | — | CN | disclosed |
| WO-2001072751-A1 | PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS | KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2001-10-04 | — | — | WO | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | LCK 1/4885SRC 46/4885TEK 1465/4885 |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | LCK 6/4885SRC 206/4885TEK 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.